New insights into MYH9 reveal expanding role in cancer and genetic disorders
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 23:16 ET (31-Oct-2026 03:16 GMT/UTC)
A comprehensive new review article highlights the growing importance of the MYH9 gene as a central player in both cancer biology and inherited genetic conditions, offering fresh perspectives on its potential as a therapeutic target.
A comprehensive new review highlights the growing importance of FOXK2, a versatile transcription factor, in shaping cancer behavior and influencing clinical outcomes across a wide range of tumor types. The article brings together emerging knowledge to clarify how this gene functions in cancer and why it is attracting increasing attention as a potential diagnostic and prognostic marker.
ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at Harvard University's David Rubenstein Treehouse in Boston. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.
ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.
Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.
DepMap scientists have generated dependency data on nearly 150 three-dimensional cancer cell models across 10 cancer types.
The updated catalog reveals cancer phenotypes, cell states, and gene dependencies that are missed in traditional cell lines and shows that both model types are complementary because each captures biology that the other misses.
The integration of data on 2D and 3D models creates a more comprehensive DepMap, moving the resource towards its goal of capturing the complete landscape of cancer vulnerabilities.